Fairmount Funds Management as of Sept. 30, 2025
Portfolio Holdings for Fairmount Funds Management
Fairmount Funds Management holds 17 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Dianthus Therapeutics (DNTH) | 11.7 | $130M | 3.3M | 39.35 | |
| Cogent Biosciences (COGT) | 11.6 | $129M | 9.0M | 14.36 | |
| Axsome Therapeutics (AXSM) | 8.9 | $99M | 815k | 121.45 | |
| Apogee Therapeutics (APGE) | 7.3 | $81M | 2.0M | 39.73 | |
| Enliven Therapeutics (ELVN) | 6.8 | $76M | 3.7M | 20.47 | |
| Miragen Therapeutics (VRDN) | 6.7 | $75M | 3.5M | 21.58 | |
| Oruka Therapeutics (ORKA) | 6.4 | $71M | 3.7M | 19.23 | |
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 6.2 | $69M | 1.8M | 38.83 | |
| Scholar Rock Hldg Corp (SRRK) | 6.1 | $68M | 1.8M | 37.24 | |
| Spyre Therapeutics Com New (SYRE) | 6.1 | $67M | 4.0M | 16.76 | |
| Nuvalent Inc-a (NUVL) | 5.7 | $63M | 728k | 86.48 | |
| Abivax Sa Sponsored Ads (ABVX) | 5.4 | $61M | 713k | 84.90 | |
| Zenas Biopharma (ZBIO) | 3.8 | $42M | 1.9M | 22.20 | |
| Jade Biosciences Com New (JBIO) | 2.5 | $28M | 3.2M | 8.63 | |
| Astria Therapeutics (ATXS) | 2.3 | $26M | 3.6M | 7.28 | |
| Crescent Biopharma (CBIO) | 1.5 | $17M | 1.4M | 11.89 | |
| Inhibikase Therapeutics Com New (IKT) | 0.9 | $9.9M | 6.1M | 1.62 |
